PL EN


Preferences help
enabled [disable] Abstract
Number of results
2018 | 18 | 4 | 373–387
Article title

Zastosowanie aripiprazolu w leczeniu zaburzeń psychicznych u dzieci i młodzieży

Content
Title variants
EN
The use of aripiprazole in the treatment of mental disorders in children and adolescents
Languages of publication
PL EN
Abstracts
EN
The article is about aripiprazole – an atypical antipsychotic that is registered in Poland for the treatment of schizophrenia in individuals aged ≥15 years, and moderate to severe manic episodes in the course of bipolar disorder type I in adolescents aged ≥13 years in the treatment lasting up to 12 weeks. The paper discusses the mechanism of action, pharmacokinetics, and safety of aripiprazole in the paediatric population. Aripiprazole acts as a partial agonist of the dopamine D2 receptor and the serotonin 5HT1A receptor. Aripiprazole pharmacokinetics in humans is linear and proportional to the dose range of 5–30 mg. In children and adolescents aged 10–17 years, the pharmacokinetic profile is comparable to that observed in adults, after the adjustment for body weight. The article also contains a review of research on the clinical efficacy of aripiprazole in the treatment of psychiatric disorders, such as: schizophrenia, bipolar disorder, hyperkinetic disorder, pervasive developmental disorders, tics and aggressive behaviours in children and adolescents. Aripiprazole evaluated in clinical trials among children and adolescents has shown a good safety and tolerability profile. The incidence and type of side effects of aripiprazole in the paediatric population are essentially similar to those observed in adults. However, by contrast with adults, adolescents treated with aripiprazole may more often develop such side effects as drowsiness, sedation, extrapyramidal symptoms, dry mouth, increased appetite, and orthostatic hypotension. Aripiprazole may play an important role in the treatment of psychiatric disorders in children and adolescents because of its favourable metabolic profile.
PL
Artykuł dotyczy aripiprazolu – atypowego leku przeciwpsychotycznego, który w Polsce jest zarejestrowany w terapii schizofrenii u osób w wieku ≥15 lat oraz epizodów maniakalnych o nasileniu umiarkowanym do ciężkiego w przebiegu zaburzenia afektywnego dwubiegunowego typu I u młodzieży w wieku ≥13 lat w leczeniu trwającym do 12 tygodni. Omówiono mechanizm działania, farmakokinetykę oraz bezpieczeństwo stosowania aripiprazolu w populacji dzieci i młodzieży. Aripiprazol działa jako częściowy agonista receptora dopaminowego D2 i serotoninowego 5HT1A. Farmakokinetyka aripiprazolu u ludzi jest liniowa i proporcjonalna do dawki w zakresie 5–30 mg. U dzieci i młodzieży w wieku 10–17 lat profil farmakokinetyczny leku jest porównywalny do obserwowanego u osób dorosłych, po korekcie różnic w masie ciała. Artykuł zawiera także przegląd badań dotyczących skuteczności klinicznej aripiprazolu w leczeniu zaburzeń psychiatrycznych, tj. schizofrenii, zaburzeń afektywnych dwubiegunowych, zaburzeń hiperkinetycznych, całościowych zaburzeń rozwojowych, tików oraz zachowań agresywnych u dzieci i młodzieży. W próbach klinicznych populacji pediatrycznej lek wykazuje dobry profil bezpieczeństwa i tolerancji. Częstość występowania i rodzaj działań niepożądanych aripiprazolu wśród dzieci i młodzieży są zasadniczo podobne jak w przypadku osób dorosłych. Jednak u młodzieży leczonej aripiprazolem mogą częściej niż u dorosłych pojawiać się efekty uboczne, takie jak senność, sedacja, objawy pozapiramidowe, suchość w jamie ustnej, wzrost apetytu i niedociśnienie ortostatyczne. Wydaje się, że aripiprazol z powodu swojego korzystniejszego profilu metabolicznego może odgrywać istotną rolę wleczeniu zaburzeń psychiatrycznych u dzieci i młodzieży.
Discipline
Publisher

Year
Volume
18
Issue
4
Pages
373–387
Physical description
Contributors
author
  • Oddział Kliniczny Psychiatrii iPsychoterapii Wieku Rozwojowego, Centrum Pediatrii im. Jana Pawła II w Sosnowcu Sp. zo.o., Sosnowiec, Polska, lenacichon@interia.pl
  • Zakład Farmakologii, Katedra Farmakologii, Wydział Lekarski w Katowicach, Śląski Uniwersytet Medyczny w Katowicach, Katowice, Polska
  • Oddział Kliniczny Psychiatrii i Psychoterapii Wieku Rozwojowego, Centrum Pediatrii im. Jana Pawła II w Sosnowcu Sp. z o.o., Sosnowiec, Polska
  • Katedra Psychiatrii i Psychoterapii, Śląski Uniwersytet Medyczny w Katowicach, Katowice, Polska; Klinika Rehabilitacji Psychiatrycznej, Wydział Lekarski w Katowicach, Śląski Uniwersytet Medyczny w Katowicach, Katowice, Polska
  • Oddział Kliniczny Psychiatrii i Psychoterapii Wieku Rozwojowego, Centrum Pediatrii im. Jana Pawła II w Sosnowcu Sp. z o.o., Sosnowiec, Polska; Katedra Psychiatrii iPsychoterapii, Śląski Uniwersytet Medyczny w Katowicach, Katowice, Polska
References
  • Algon S, Yi J, Calkins ME et al.: Evaluation and treatment of children and adolescents with psychotic symptoms. Curr Psychiatry Rep 2012; 14: 101–110.
  • Asarnow RF, Forsyth JK: Genetics of childhood-onset schizophrenia. Child Adolesc Psychiatr Clin N Am 2013; 22: 675–687.
  • Axelson D, Birmaher B, Strober M et al.: Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 2006; 63: 1139–1148.
  • Bastiaens L: A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic. Community Ment Health J 2009; 45: 73–77.
  • Biederman J, Mick E, Spencer T et al.: An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 2007; 12: 683–689.
  • Blankenship K, Erickson CA, Stigler KA et al.: Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6–17 years. Ped Health 2010; 4: 375–381.
  • Bolonna AA, Kerwin RW: Partial agonism and schizophrenia. Br J Psychiatry 2005; 186: 7–10. Bryńska A, Wolańczyk T: Dziecko z zaburzeniami tikowymi w szkole i przedszkolu. Ośrodek Rozwoju Edukacji, Warszawa 2010.
  • Bush G: Attention-deficit/hyperactivity disorder and attention networks. Neuropsychopharmacology 2010; 35: 278–300.
  • DeLeon A, Patel NC, Crismon ML: Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004; 26: 649–666.
  • Driver DI, Gogtay N, Rapoport JL: Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. Child Adolesc Psychiatr Clin N Am 2013; 22: 539–555.
  • Esposito-Smythers C, Birmaher B, Valeri S et al.: Child comorbidity, maternal mood disorder, and perceptions of family functioning among bipolar youth. J Am Acad Child Adolesc Psychiatry 2006; 45: 955–964.
  • Findling RL, Kauffman R, Sallee FR et al.: An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol 2009a; 19: 431–439.
  • Findling RL, McNamara NK, Youngstrom EA et al.: An open-label study of aripiprazole in children with a bipolar disorder. J Child Adolesc Psychopharmacol 2011; 21: 345–351.
  • Findling RL, Nyilas M, Forbes RA et al.: Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2009b; 70: 1441–1451.
  • Findling RL, Robb A, Nyilas M et al.: A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008a; 165: 1432–1441.
  • Findling RL, Short EJ, Leskovec T et al.: Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008b; 18: 347–354.
  • Gardner DM, Baldessarini RJ, Waraich P: Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172: 1703–1711.
  • Ghanizadeh A, Haghighi A: Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial. Child Psychiatry Hum Dev 2014; 45: 596–603.
  • Ghanizadeh A, Sahraeizadeh A, Berk M: A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev 2014; 45: 185–192.
  • Greenaway M, Elbe D: Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2009; 18: 250–260.
  • Hirose T, Kikuchi T: Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest 2005; 52 Suppl: 284–290.
  • Ho JG, Caldwell RL, McDougle CJ et al.: The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2012; 22: 277–283.
  • Kirino E: Efficacy and safety of aripiprazole in child and adolescent patients. Eur Child Adolesc Psychiatry 2012; 21: 361–368.
  • Kumar A, Datta SS, Wright SD et al.: Atypical antipsychotics for psychosis in adolescents. Cochrane Database Syst Rev 2013; (10): CD009582.
  • Leibenluft E: Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths. Am J Psychiatry 2011; 168: 129–142.
  • Lewinsohn PM, Klein DN, Seeley JR: Bipolar disorder during adolescence and young adulthood in a community sample. Bipolar Disord 2000; 2: 281–293.
  • Mailman RB, Murthy V: Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 2010; 16: 488–501.
  • Marcus RN, Owen R, Kamen L et al.: A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009; 48: 1110–1119.
  • Marcus RN, Owen R, Manos G et al.: Aripiprazole in the treatment of irritability in pediatric patients (aged 6–17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol 2011a; 21: 229–236.
  • Marcus RN, Owen R, Manos G et al.: Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry 2011b; 72: 1270–1276.
  • Nigg JT: Attention-deficit/hyperactivity disorder and adverse health outcomes. Clin Psychol Rev 2013; 33: 215–228.
  • Oh J, Chang JG, Lee SB et al.: Comparison of aripiprazole and other atypical antipsychotics for pediatric bipolar disorder: a retrospective chart review of efficacy and tolerability. Clin Psychopharmacol Neurosci 2013; 11: 72–79.
  • Owen R, Sikich L, Marcus RN et al.: Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009; 124: 1533–1540.
  • Perlis RH, Miyahara S, Marangell LB et al.; STEP-BD Investigators: Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2004; 55: 875–881.
  • Renk K, White R, Lauer BA et al.: Bipolar disorder in children. Psychiatry J 2014; 2014: 928685.
  • Seo WS, Sung HM, Sea HS et al.: Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 2008; 18: 197–205.
  • Sheehan JJ, Sliwa JK, Amatniek JC et al.: Atypical antipsychotic metabolism and excretion. Curr Drug Metab 2010; 11: 516–525.
  • Shprecher D, Kurlan R: The management of tics. Mov Disord 2009; 24: 15–24.
  • Stigler KA, Diener JT, Kohn AE et al.: Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 2009; 19: 265–274.
  • Stigler KA, Posey DJ, McDougle CJ: Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004; 14: 455–463.
  • Summary of product characteristics – aripiprazole. Temcheff CE, Serbin LA, Martin-Storey A et al.: Childhood aggression, withdrawal and likeability, and the use of health care later: a longitudinal study. CMAJ 2011; 183: 2095–2101.
  • Tramontina S, Zeni CP, Ketzer CR et al.: Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/ hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry 2009; 70: 756–764.
  • Van Meter AR, Moreira AL, Youngstrom EA: Meta-analysis of epidemiologic studies of pediatric bipolar disorder. J Clin Psychiatry 2011; 72: 1250–1256.
  • Whitney Z, Boyda HN, Procyshyn RM et al.: Therapeutic drug levels of second generation antipsychotics in youth: a systematic review. J Child Adolesc Psychopharmacol 2015; 25: 234–245.
  • Woods SW, Tully EM, Walsh BC et al.: Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 2007; 51: s96–s101.
  • Yokoi F, Gründer G, Biziere K et al.: Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002; 27: 248–259.
  • Yoo HK, Joung YS, Lee JS et al.: A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry 2013; 74: e772–e780.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-58f1becd-6e94-411f-87f9-a6c518f5ba23
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.